Kevin Zorn, MD, FRCSC, FACS, presented “Management of Obstructive LUTS in Men with Prostate Cancer” during the 2024 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on October 18, 2024, in San Diego, California.
>
How to cite: Zorn, Kevin. “Management of Obstructive LUTS in Men with Prostate Cancer.” October, 2024. Accessed Jul 2025. https://grandroundsinurology.com/management-of-obstructive-luts-in-men-with-prostate-cancer/
Management of Obstructive LUTS in Men with Prostate Cancer – Summary
Kevin Zorn, MD, FRCSC, FACS, explores the management of obstructive lower urinary tract symptoms (LUTS) in men with prostate cancer, including those under active surveillance, post-radiation therapy, or focal treatment. Emphasizing personalized care, this 15-minute presentation underscores the complexity of LUTS management in this diverse patient population.
Dr. Zorn highlights the importance of thorough evaluations, starting with a complete history, physical examination, and diagnostic tools like uroflowmetry, bladder scans, and cystoscopy. Not all LUTS are obstructive; alternative diagnoses such as overactive bladder, urethral strictures, or neurological conditions must be ruled out. The interplay of radiation, hormonal therapy, and prostate tissue changes further complicates management. Dr. Zorn advocates for tailored treatment strategies based on individual needs.
Emerging technologies like focal ablation are discussed as potential dual-purpose treatments for cancer and BPH. Challenges such as tissue fibrosis, stromal changes, and the delayed effects of radiation therapy on healing are addressed, emphasizing the need for cautious surgical planning. Dr. Zorn emphasizes the importance of individualized care and multidisciplinary collaboration to optimize outcomes.
Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies.
ABOUT THE AUTHOR
Kevin C. Zorn, MD, FACS, FRCSC, is the founder of the BPH Canada Prostate Institute, a personalized, private, prostate solution center founded in 2023 to offer all approved BPH therapies to Canadian men, and director of Robotic & MIS BPH Prostate Surgery, Mont-Royal Surgical Center. Dr. Zorn is a former associate professor of urology at the University of Montreal (CHUM) and the University of Chicago, sub-specializing in robotic surgery and benign prostatic hyperplasia (BPH) surgical care.
Dr. Zorn attended McGill University for his pre-med program, his medical degree, and his residency in urological surgery. He became a fellow of the Royal College of Physicians and Surgeons of Canada (FRCSC) in 2005. Dr. Zorn also completed a two-year fellowship in oncology and endourology at the University of Chicago. In 2007, he became American Board of Urology certified in urology and a fellow of the American College of Surgeons.
Research and innovation have been the hallmarks of Dr. Zorn’s career. Among his many firsts, he was the first in Canada and Québec to use many new BPH technologies, including Greenlight XPS, Rezum, iTind, Optilume, Aquablation and Zenflow. He has also been the first in Canada to introduce cutting-edge technologies including the Clarius and ButterflyIQ point-of care ultrasound (POCUS), as well as disposable AMBU4 cystoscopes for faster patient care and greater safety. He is among the first physicians globally to be named as a Center of Excellence for Rezum and Greenlight vaporization and VIT (vapor incision technique). He is an international speaker and surgical trainer for these techniques.
Dr. Zorn is the senior author of the Male lower urinary tract symptoms (LUTS)/BPH guidelines for the 2018 and 2022 Canadian Urological Association (CUA) and consulted on the American Urological Association BPH guidelines. He has also helped create national online programs in robotic prostate cancer care and rehabilitation as well as the CUA BPH patient decision-aid tool. Dr. Zorn has authored 400 peer-reviewed publications and 12 book chapters on BPH and minimally invasive surgical care. With such accolades, Dr. Zorn has become a sought-afterspeaker, teacher and researcher. He has traveled to lecture, teach, and proctor surgery around the world, and is intimately involved with the development of several pioneering BPH technologies. In 2024, Dr. Zorn retired from his position at the University of Montreal to dedicate his full clinical practice to BPH Canada.
